163 related articles for article (PubMed ID: 32209331)
1. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
Dou X; Qin Y; Lai Y; Shi H; Huang X; Jiang Q
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e304-e315. PubMed ID: 32209331
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
Bonifacio M; Scaffidi L; Binotto G; Miggiano MC; Danini M; Minotto C; Griguolo D; Marin L; Frison L; D'Amore F; Basso M; Sartori R; Tinelli M; Stulle M; Fortuna S; Bonalumi A; Bertoldero G; De Biasi E; Ruggeri M; Semenzato G; Fanin R; Pizzolo G; Krampera M; Tiribelli M
Leuk Res; 2018 Nov; 74():75-79. PubMed ID: 30308414
[TBL] [Abstract][Full Text] [Related]
4. [A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study].
Shi HX; Qin YZ; Lai YY; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):922-926. PubMed ID: 27916045
[No Abstract] [Full Text] [Related]
5. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
[No Abstract] [Full Text] [Related]
6. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
[TBL] [Abstract][Full Text] [Related]
7. Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
Scalzulli E; Colafigli G; Latagliata R; Pepe S; Diverio D; Stocchi F; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Dec; 99(12):2773-2777. PubMed ID: 32462330
[TBL] [Abstract][Full Text] [Related]
8. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
9. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
[No Abstract] [Full Text] [Related]
10. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
Dou X; Zheng F; Zhang L; Jin J; Zhang Y; Liu B; Meng L; Zhu X; Lu Z; Jia Y; Liu H; Lin H; Zhou L; Zhao X; Yang W; Sun H; Qian S; Ma H; Du X; Bai Q; Xu N; Meng F; Jia Z; Di H; Zhang L; Jiang Q
Ann Hematol; 2021 Sep; 100(9):2215-2228. PubMed ID: 34089385
[TBL] [Abstract][Full Text] [Related]
11. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Awidi A; Abbasi S; Alrabi K; Kheirallah KA
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e55-e61. PubMed ID: 28844599
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
Abou Dalle I; Kantarjian H; Burger J; Estrov Z; Ohanian M; Verstovsek S; Ravandi F; Borthakur G; Garcia-Manero G; Jabbour E; Cortes J
Cancer Med; 2019 Nov; 8(15):6559-6565. PubMed ID: 31502383
[TBL] [Abstract][Full Text] [Related]
13. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
14. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):728-736. PubMed ID: 38049316
[No Abstract] [Full Text] [Related]
15. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Ćojbašić Ž
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e526-e531. PubMed ID: 31239209
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
[TBL] [Abstract][Full Text] [Related]
17. [Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
Zhang XS; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):54-62. PubMed ID: 35231994
[No Abstract] [Full Text] [Related]
18. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
Ostojic A; Sertic D; Roncevic P; Peric Z; Granic P; Matic N; Basic-Kinda S; Serventi-Seiwerth R; Radman I; Zadro R; Nemet D
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):472-6. PubMed ID: 27245313
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
Nakamae H; Fujisawa S; Ogura M; Uchida T; Onishi Y; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Ohashi K; Li L; Miyoshi M
Int J Hematol; 2017 Jun; 105(6):792-804. PubMed ID: 28341918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
